Results 1 to 10 of about 5,866,745 (304)

Toll-like receptor 5 on monocyte as a biomarker of mortality risk in patients with sepsis [PDF]

BMC Infectious Diseases
Objective To evaluate the expression of Toll-like receptor 5 on monocyte at ICU admission as a potentially novel early screening biomarker to predict the mortality risk of sepsis.
Hong Tan, Hanyi Wang, Xuanyi Zhou, Wenjun Que, Xiaoliang Yang   +4 more
doaj   +2 more sources

TLR9: A Double-Dealing Toll-Like Receptor [PDF]

ImmunoTargets and Therapy
Megan Nielsen,1 Daisuke Nishizaki,2,* Shumei Kato,2,* Razelle Kurzrock1 1Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA; 2Moores Cancer Center, University of California San Diego, La Jolla, CA, USA*These ...
Nielsen M, Nishizaki D, Kato S, Kurzrock R   +3 more
doaj   +2 more sources

How Toll-like receptors influence Parkinson’s disease in the microbiome–gut–brain axis

Frontiers in Immunology, 2023
Recently, a large number of experimenters have found that the pathogenesis of Parkinson’s disease may be related to the gut microbiome and proposed the microbiome–gut–brain axis.
Ziyi Zhang, Ziyi Zhang, Zhihui Liu, Ao Lv, Chenhui Fan   +4 more
doaj   +1 more source

Involvement of Toll-Like Receptor 4 in Decreased Vasopressor Response Following Trauma/Hemorrhagic Shock

Critical Care Explorations, 2021
OBJECTIVES:. Refractory vascular failure due to the inability of vascular smooth muscle to respond to vasoconstrictors such as phenylephrine is a final common pathway for severe circulatory shock of any cause, including trauma/hemorrhagic shock ...
Rafi Mazor, PhD, Fernando Dos Santos, PhD, Joyce B. Li, MSc, Federico Aletti, PhD, Geert Schmid-Schonbein, PhD, Erik B. Kistler, MD, PhD   +5 more
doaj   +1 more source

Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma

Journal of Hematology & Oncology, 2021
Glioma represents a fast proliferating and highly invasive brain tumor which is resistant to current therapies and invariably recurs. Despite some advancements in anti-glioma therapies, patients’ prognosis remains poor.
Yang Xun, Hua Yang, Bozena Kaminska, Hua You   +3 more
doaj   +1 more source

TLR7 Ligation Inhibits TLR8 Responsiveness in IL-27-Primed Human THP-1 Monocytes and Macrophages

Journal of Innate Immunity, 2021
Regulation of proinflammatory cytokine expression is critical in the face of single-stranded RNA (ssRNA) virus infections. Many viruses, including coronavirus and influenza virus, wreak havoc on the control of cytokine expression, leading to the ...
Natalya Odoardi, Olena Kourko, Carlene Petes, Sameh Basta, Katrina Gee   +4 more
doaj   +1 more source

Human and Bacterial Toll-Interleukin Receptor Domains Exhibit Distinct Dynamic Features and Functions

Molecules, 2022
Toll-interleukin receptor (TIR) domains have emerged as critical players involved in innate immune signaling in humans but are also expressed as potential virulence factors within multiple pathogenic bacteria.
Eunjeong Lee, Jasmina S. Redzic, Travis Nemkov, Anthony J. Saviola, Monika Dzieciatkowska, Kirk C. Hansen, Angelo D’Alessandro, Charles Dinarello, Elan Z. Eisenmesser   +8 more
doaj   +1 more source

Toll-Like Receptor 4 Wild Type Homozygozity of Polymorphisms +896 and +1196 Is Associated with High Gastrin Serum Levels and Peptic Ulcer Risk. [PDF]

PLoS ONE, 2015
Toll-like receptor 4 is a part of the innate immune system and recognizes Helicobacter pylori lipopolysaccharide. The goal of this study was to analyze the role of Toll-like receptor 4 polymorphisms +896 (rs4986790) and +1196 (rs4986791) in the ...
Vesa-Matti Pohjanen, Olli-Pekka Koivurova, Heikki Huhta, Olli Helminen, Johanna M Mäkinen, Jari M Karhukorpi, Tapio Joensuu, Pentti O Koistinen, Jarno M Valtonen, Seppo E Niemelä, Riitta A Karttunen, Tuomo J Karttunen   +11 more
doaj   +1 more source

Role of Toll Like Receptor 4 in Alzheimer’s Disease

Frontiers in Immunology, 2020
Long-term evidence has confirmed the involvement of an inflammatory component in neurodegenerative disorders including Alzheimer’s disease (AD). This view is supported, in part, by data suggesting that selected non-steroidal anti-inflammatory drugs ...
Maria Calvo-Rodriguez, Carmen García-Rodríguez, Carlos Villalobos, Lucía Núñez, Lucía Núñez   +4 more
doaj   +1 more source

Toll-like receptor 2 or toll-like receptor 4 deficiency does not modify lupus in MRLlpr mice.

PLoS ONE, 2013
Systemic lupus erythematosus is an autoimmune disease with a high morbidity and nephritis is a common manifestation. Previous studies in murine lupus models have suggest a role for Toll-like receptor 2 and 4.
Simon J Freeley, Angela Giorgini, Calogero Tulone, Reena J Popat, Catherine Horsfield, Michael G Robson   +5 more
doaj   +1 more source